Target intelligence / Profile preview

Peptidoglycan D,D-transpeptidase MrdA (PBP2)

Target
PBP2
Molecular classification
Enzyme (Serine-type D-Ala-D-Ala carboxypeptidase), Penicillin-binding protein (Class B), Transpeptidase
01

Overview

Peptidoglycan D,D-transpeptidase MrdA—commonly known as penicillin-binding protein 2 (PBP2)—is an essential membrane-bound enzyme found in Gram-negative bacteria such as *Escherichia coli*. It catalyzes the cross-linking step during peptidoglycan biosynthesis by forming peptide bonds between adjacent glycan strands, which provides mechanical strength and rigidity to the bacterial cell wall. This activity is crucial for maintaining rod-shaped morphology and proper cellular growth. The inhibition of MrdA/PBP2 by β-lactam antibiotics disrupts peptidoglycan assembly, leading to loss of structural integrity and ultimately bacterial lysis. Due to its central role in cell wall synthesis and its absence from eukaryotic cells, it serves as a major therapeutic target for antibacterial agents targeting infectious diseases caused by susceptible bacteria.

Other names
Penicillin-binding protein 2PBP-2PBP2Class B penicillin-binding protein 2Transpeptidase PBP2TP PBP2EC 3.4.16.4
02

Mechanism of action

Inhibition of peptidoglycan cross-linking by covalent binding to the active serine residue within the transpeptidase domain. Disruption of bacterial cell wall synthesis resulting in bacteriolysis or loss of viability.

03

Biological functions

Peptidoglycan cross-linking in cell wall biosynthesisDetermination of rod shape in bacteria (cell morphogenesis)Cell wall organization and maintenance of cell diameter during growth
04

Disease associations

Infection (targeted by antibiotics to treat bacterial infections)
05

Safety considerations

Emergence of antibiotic resistance due to mutations or acquisition of alternative penicillin-binding proteins.Off-target effects are not relevant since this is a prokaryotic-specific enzyme absent from humans.
06

Interacting drugs

Amoxicillin

2 more in the full profile.

07

Biomarkers

No specific clinical biomarkers for patient selection are established for this target; however, resistance mechanisms such as altered expression or mutation can be monitored in microbiology labs.

Beyond the preview

Go deeper on Peptidoglycan D,D-transpeptidase MrdA (PBP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan D,D-transpeptidase MrdA (PBP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call